Project description
New regenerative implant to prevent total knee replacement
Knee cartilage deterioration or injuries are often the cause of osteoarthritis. This chronic disease associated with pain, stiffness and severe disability decreases the quality of life and represents a serious economic burden for health systems. However, existing treatments such as total knee joint replacement are expensive and often involve complications. The EU-funded FibroFix Cartilage project proposes a regenerative orthopaedic implant that addresses the problem of large and/or osteoarthritic articular cartilage lesions in the knee. The silk-based implant is biostable and biocompatible, emulating cartilage function and supporting cartilage regeneration at a significantly lower cost than other solutions. The product allows prolonged use of the joint, increases mobility, reduces pain and postpones or prevents total knee replacement.
Objective
FibroFix™ Cartilage, silk-based implant for cartilage repair and regeneration, introducing a new paradigm in osteoarthritis treatment.
Cartilage deterioration and injuries often lead to osteoarthritis (OA) – a long-term chronic disease resulting in bones rubbing together and creating pain, stiffness and severe disability. Knee cartilage injuries are very common and almost half of them go on to develop OA, which is second only to heart disease as a cause of work disability. Resulting from decreased quality
of life, hospitalizations and loss of productivity, the economic cost of OA is particularly high in every country that it has been estimated. Currently, all treatments available, including Total Knee joint Replacement (TKR) as the ultimate recourse, are inefficient and expensive: they involve pain, lengthy rehabilitation, frequent complications and high costs. Therefore, given
the increasing prevalence of knee OA, its associated burdens and the drawbacks of all available treatments, it is becoming increasingly important to develop an innovative cost-effective solution to this major public health problem worldwide.
FibroFix™ Cartilage is a well characterised, regenerative orthopaedic repair product to address the unmet and pressing clinical need of large and/or osteoarthritic articular cartilage lesions in the knee, developed by Orthox. It is biostable, biocompatible, emulates cartilage function and supports cartilage regeneration at the minimum cost effectiveness ratio. It allows resurfacing of large and/or potentially OA cartilage lesions, prolonged use of the joint, increased mobility, reduced pain and postponement or prevention of TKR. Smooth, robust, resilient, durable and lubricious, it is a unique combination to be applied in orthopaedics and biomaterials shifting the paradigm in knee OA treatment and up to 10 times less expensive than other solutions.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.
- medical and health scienceshealth sciencespublic health
- medical and health sciencesclinical medicinephysiotherapy
- social scienceseconomics and businesseconomicsproduction economicsproductivity
- medical and health sciencesclinical medicineorthopaedics
- engineering and technologyindustrial biotechnologybiomaterials
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Programme(s)
Call for proposal
(opens in new window) H2020-EIC-SMEInst-2018-2020
See other projects for this callSub call
H2020-EIC-SMEInst-2018-2020-3
Funding Scheme
SME-2 - SME instrument phase 2Coordinator
OX14 4RQ Abingdon
United Kingdom
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.